A randomized trial on tamoxifen continuation during second-line hormone therapy in breast cancer.
Pronzato
P
P
National Institute for Cancer Research, Genova, Italy.
Bertelli
G
G
Rosso
M
M
D000616:Aminoglutethimide / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use* / Q000633:toxicity
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D000616:Aminoglutethimide; C021650:hydrocortisone acetate; D006854:Hydrocortisone